Kyverna Therapeutics News

Kyverna Therapeutics | 10-Q: Quarterly report

SEC announcementMay 14 16:35 ET · Announcements

Express News | Kyverna Therapeutics Q1 2024 Adj EPS $(1.12) Misses $(0.84) Estimate

BenzingaMay 14 16:34 ET

Express News | Kyverna Therapeutics Inc: Qtrly Shr Loss $1.12

ReutersMay 14 16:27 ET

Express News | Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

ReutersMay 14 16:05 ET

8 Out of 12 S&P 500 Healthcare Companies Beat Profit Consensus This Week: Earnings Scorecard

Seeking AlphaMay 12 11:22 ET

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it

BenzingaApr 29 13:04 ET

Express News | Kyverna Therapeutics To Attend The 2024 AAN Annual Meeting With Data On KYV-101 In Treatment Of Patients With Neurological Autoimmune Diseases

Moomoo 24/7Apr 11 17:16 ET

Kyverna Therapeutics to Attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients With Neurological Autoimmune Diseases

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for...

PR NewswireApr 11 17:01 ET

12 Health Care Stocks Moving In Monday's After-Market Session

GainersOpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares in

BenzingaApr 1 16:31 ET

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med

Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies The trea

PR NewswireMar 29 14:59 ET

Kyverna Therapeutics FY23 EPS $(89.61) Vs $(63.43) YoY

Financial Results for the Year Ended December 31, 2023For the year ended December 31, 2023, the company reported a net loss of $60.4 million, or a net loss per common share of $89.61, compared to a ne

BenzingaMar 26 16:20 ET

Kyverna Therapeutics 2023 R&D Expenses $49.9M >KYTX

Kyverna Therapeutics 2023 R&D Expenses $49.9M >KYTX

Dow JonesMar 26 16:06 ET

Press Release: Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results PR Newswire EMERYVILLE, Calif., March 26, 2024 -- Advanced clinical development in two broad areas of a

Dow JonesMar 26 16:05 ET

Heard on the Street: Why That Hot Biotech IPO Could Be a Winner -- WSJ

By David Wainer The best time to make money in biotech is usually during periods of cautious optimism. There are strong signs that right now might be one of those moments. The always-volatile indust

WSJMar 14 07:00 ET

Sector Update: Health Care Stocks Steady Pre-Bell Friday

Health care stocks were steady pre-bell Friday as the iShares Biotechnology ETF (IBB) was inactive and the Health Care Select Sector SPDR Fund (XLV) was up a slight 0.1% recently. Amylyx Pharmaceutica

MT NewswiresMar 8 09:17 ET

Kyverna Therapeutics And Stanford University Collaborate To Evaluate KYV-101 In Patients With Non-Relapsing And Progressive Forms Of Multiple Sclerosis

The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participantsThe clinical study wil

BenzingaMar 8 02:20 ET

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients With Non-Relapsing and Progressive Forms of Multiple Sclerosis

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients...

PR NewswireMar 7 19:26 ET

How Kyverna Is Positioned for Success on Autoimmune Therapy: CEO

Yahoo FinanceMar 7 18:14 ET

Kyverna Therapeutics Price Target Announced at $39.00/Share by JP Morgan

Kyverna Therapeutics Price Target Announced at $39.00/Share by JP Morgan

Dow JonesMar 4 06:39 ET

Kyverna Therapeutics Initiated at Overweight by Morgan Stanley

Kyverna Therapeutics Initiated at Overweight by Morgan Stanley

Dow JonesMar 4 06:19 ET